Skip to main content

Advertisement

SpringerLink
Log in

Interleukin-6

Potential Clinical Applications in Cancer Therapy

  • Review Article
  • Disease Treatment Review
  • Published:
Clinical Immunotherapeutics Aims and scope Submit manuscript

Summary

Interleukin-6 (IL-6) is secreted primarily by macrophages in response to inflammatory stimuli. It mediates the inflammatory response by: (a) stimulating the production of acute phase proteins; (b) functioning as a factor in terminal B cell differentiation; and (c) providing an activation signal to peripheral T cells. IL-6 stimulates haemopoietic maturation by inducing stem cells into the cell cycle and, through synergism with other cytokines, in promoting colony formation. It also functions as a thrombopoietin in normal and irradiated animals. Antitumour activity has been documented in murine tumour systems.

Based on the preclinical activity of recombinant human (rh) IL-6 we conducted a phase I study in 42 patients with refractory malignancy. Flu-like toxicity was observed. Significant dosage-related thrombocytosis and monocytosis were also documented. A partial response was noted in 1 patient with non-small-cell lung cancer. In a separate study, when rhIL-6 was administered after chemotherapy for sarcoma, accelerated platelet recovery was noted in the patients treated with rhIL-6. Clinical trials investigating the haemopoietic activity of rhIL-6 are ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weissenbach J, Chernajovsky Y, Zeevi M, et al. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci USA 1980; 77: 7152–6

    Article  PubMed  CAS  Google Scholar 

  2. Sehgal PB, Sagar AD. Heterogeneity of poly(I)-poly(C)-induced human fibroblast interferon mRNA species. Nature 1980; 288: 95–7

    Article  PubMed  CAS  Google Scholar 

  3. Content J, DeWit L, Pierard D, et al. Secretory proteins induced in human fibroblasts under conditions used for the production of interferon β. Proc Natl Acad Sci USA 1980; 79: 2768–72

    Article  Google Scholar 

  4. Van Damme J, Opdenakker G, Simpon R, et al. Identification of the human 26-kD protein, interferon β2 (IFN-β2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 1987; 165: 914–9

    Article  PubMed  Google Scholar 

  5. Zilberstein A, Ruggieri R, Korn JH, et al. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulating cytokines. EMBO J 1986; 5: 2529–37

    PubMed  CAS  Google Scholar 

  6. Haegeman G, Content J, Volckaert G, et al. Structural analysis of the sequence coding for an inducible 25kDa protein in human fibroblasts. Eur J Biochem 1986; 159: 625–32

    Article  PubMed  CAS  Google Scholar 

  7. Muraguchi A, Kishimoto T, Miki Y, et al. T cell replacing factor (TRF)-induced IgG secretion in human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 1981; 127: 412–6

    PubMed  CAS  Google Scholar 

  8. Teranishi T, Hirano T, Naomichi A, et al. Human helper T cell factor(s) (ThF). II. Induction of IgG production in B lymphoblastoid cell lines and identification of T cell-replacing factor (TRF)-like factor(s). J Immunol 1982; 128: 193–8

    Google Scholar 

  9. Hirano T, Taga T, Nakano N, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 1985; 82: 5490–4

    Article  PubMed  CAS  Google Scholar 

  10. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324: 73–6

    Article  PubMed  CAS  Google Scholar 

  11. Hirano T, Teranishi T, Lin B, et al. Human helper T cell factor(s). IV. Demonstration of a human late-acting B cell differentiation factor acting on Staphylococcus aureus Cowan I-stimulated B cells. J Immunol 1984; 133: 798–802

    PubMed  CAS  Google Scholar 

  12. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992; 62: 560–5

    Article  Google Scholar 

  13. Takai Y, Wong G, Clark S, et al. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 1988; 140: 508–12

    PubMed  CAS  Google Scholar 

  14. Ritchie DG, Fuller GM. Hepatocyte-stimulating factor: a monocyte-derived acute phase regulatory protein. Ann NY Acad Sci 1983; 408: 490–502

    Article  PubMed  CAS  Google Scholar 

  15. Gauldie J, Richards C, Harnish D, et al. Interferon B2/B cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulatory factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987; 84: 7251–5

    Article  PubMed  CAS  Google Scholar 

  16. Poupart P, Vandenabeele P, Cayphas S, et al. B cell growth modulating and differentiating activity of recombinant human 26-kD protein (BSF-2, HuIFN-B2, HPGF). EMBO J 1987; 6: 1219–24

    PubMed  CAS  Google Scholar 

  17. Paul WE, Laughlin CA, Johnston MI. Report of nomenclature discussion. Ann NY Acad Sci 1989; 557: 579–580

    Article  Google Scholar 

  18. Sehgal PB. Interleukin-6: molecular pathophysiology. J Invest Dermatol 1990; 94: 2S–6S

    Article  PubMed  CAS  Google Scholar 

  19. May LT, Viguet H, Kenney JS, et al. High levels of ‘complexed’ interleukin-6 in human blood. J Biol Chem 1992; 267: 19698–704

    PubMed  CAS  Google Scholar 

  20. Matsuda T, Hirano T, Nagasawa S, et al. Identification of α2-macroglobulin as a carrier protein for IL-6. J Immunol 1989; 142: 148–52

    PubMed  CAS  Google Scholar 

  21. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253–78

    Article  PubMed  Google Scholar 

  22. Bowcock AM, Kidd JR, Lathrop MG, et al. The human ‘beta-2 interferon/hepatocyte stimulating factor/interleukin-6’ gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics 1988; 3: 8–16

    Article  PubMed  CAS  Google Scholar 

  23. Walther Z, May LT, Sehgal PB. Transcriptional regulation of the interferon-β2/B cell differentiation factor BSF-2/hepatocytestimulating factor gene in human fibroblasts by other cytokines. J Immunol 1988; 140: 974–7

    PubMed  CAS  Google Scholar 

  24. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1–10

    PubMed  CAS  Google Scholar 

  25. Akira S, Hirano T, Taga T, et al. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990; 4: 2860–7

    PubMed  CAS  Google Scholar 

  26. Gruss H, Brach M, Herrmann F. Involvement of nuclear factor-κB in induction of the interleukin-6 gene by leukemia inhibitory factor. Blood 1992; 80: 2563–70

    PubMed  CAS  Google Scholar 

  27. Navarro S, Debiti N, Bernaudin J, et al. Regulation of the expression of IL-6 in human monocytes. J Immunol 1989; 142: 4339–45

    PubMed  CAS  Google Scholar 

  28. Sironi M, Breviario F, Proserpio P, et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol 1989; 142: 549–53

    PubMed  CAS  Google Scholar 

  29. Jablons DM, Mulé JJ, McIntosh JK, et al. IL-6/IFN-B-2 as a circulating hormone. J Immunol 1989; 142: 1542–7

    PubMed  CAS  Google Scholar 

  30. May L, Ghrayeb J, Santhanem U, et al. Synthesis and secretion of multiple forms of B2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem 1988; 263: 7760–6

    PubMed  CAS  Google Scholar 

  31. Rola-Pleszczynski M, Stankova J. Leukotriene B4 enhances interleukin-6 (IL-6) production and IL-6 messenger RNA accumulation in human monocytes in vitro: transcriptional and post transcriptional mechanisms. Blood 1992; 80: 1004–11

    PubMed  CAS  Google Scholar 

  32. Lotz M. Interleukin-6. Cancer Invest 1993; 11: 732–42

    Article  PubMed  CAS  Google Scholar 

  33. Aarden LA, de Groot ER, Schaap OL, et al. Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987; 17: 1411–6

    Article  PubMed  CAS  Google Scholar 

  34. Grossman R, Krueger J, Yourish D, et al. Interleukin-6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86: 6367–71

    Article  PubMed  CAS  Google Scholar 

  35. Yoshizaki K, Nishimoto N, Matsumoto K, et al. Interleukin-6 and expression of its receptor on epidermal keratinocytes. Cytokine 1990; 2: 381–7

    Article  PubMed  CAS  Google Scholar 

  36. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 1991; 5: 171–7

    PubMed  CAS  Google Scholar 

  37. Hamid Q, Barkans J, Meng Q, et al. Human eosinophils synthesize and secrete interleukin-6 in vitro. Blood 1992; 80: 1496–501

    PubMed  CAS  Google Scholar 

  38. Vankelecom H, Carmeliet P, Van Damme J, et al. Production of interleukin-6 by folliculo-stellate cells of the interior pituitary gland in a histiotypic cell aggregate culture system. Neuroendocrinology 1987; 120: 685–91

    Google Scholar 

  39. Tovey MG, Content J, Gresser I, et al. Genes for IFN-B-2 (IL-6), tumor necrosis factor and IL-1 are expressed at high levels in the organs of normal individuals. J Immunol 1988; 141: 3106–10

    PubMed  CAS  Google Scholar 

  40. Hack CE, de Groot ER, Felt-Bersma JF, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704–10

    PubMed  CAS  Google Scholar 

  41. Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin’s disease and with B symptoms. Cancer Res 1993; 53: 2118–22

    PubMed  CAS  Google Scholar 

  42. Nijsten MW, de Groot ER, ten Duis HJ, et al. Serum levels of interleukin-6 and acute phase responses. Lancet 1987; 2: 921

    Article  PubMed  CAS  Google Scholar 

  43. Hirano T, Matsuda T, Turner M, et al. Excessive production of interleukin-6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18: 1797–801

    Article  PubMed  CAS  Google Scholar 

  44. Houssiau FA, Devogelaer JP, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784–8

    Article  PubMed  CAS  Google Scholar 

  45. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathological significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989; 74: 1360–7

    PubMed  CAS  Google Scholar 

  46. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–5

    Article  PubMed  CAS  Google Scholar 

  47. Reibnegger G, Krainer M, Herold M, et al. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991; 51: 6250–3

    PubMed  CAS  Google Scholar 

  48. Gogusev J, Augusti M, Chretien Y, et al. Interleukin-6 and TNF alpha production in human renal cell carcinoma. Kidney Int 1993; 44: 585–92

    Article  PubMed  CAS  Google Scholar 

  49. Miki S, Iwano M. Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett 1989; 250: 607–10

    Article  PubMed  CAS  Google Scholar 

  50. Ohzato H, Yoshizaki K, Nishimoto N, et al. Interleukin-6 as a new indicator of inflammatory status: detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 1992; 111: 201–9

    PubMed  CAS  Google Scholar 

  51. Nishimoto N, Yoshizaki K, Tagoh H, et al. Elevation of serum interleukin-6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol 1989; 50: 399–401

    Article  PubMed  CAS  Google Scholar 

  52. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317–22

    PubMed  CAS  Google Scholar 

  53. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994; 76: 253–62

    Article  PubMed  CAS  Google Scholar 

  54. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992; 258: 593–7

    Article  PubMed  CAS  Google Scholar 

  55. Akira S, Nishio Y, Inoue M, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994; 77: 63–71

    Article  PubMed  CAS  Google Scholar 

  56. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339–42

    Article  PubMed  CAS  Google Scholar 

  57. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for terminal differentiation of B cells. J Exp Med 1988; 167: 332–44

    Article  PubMed  CAS  Google Scholar 

  58. Emilie D, Crevon MC, Auffredou MT, et al. Glucocorticosteroid-dependent synergy between interleukin-1 and interleukin-6 for human B lymphocyte differentiation. Eur J Immunol 1988; 18: 2043–7

    Article  PubMed  CAS  Google Scholar 

  59. Noma T, Mizuta T, Rosen A, et al. Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotrophic lymphokines. Immunol Lett 1987; 15: 249–53

    Article  PubMed  CAS  Google Scholar 

  60. Helle M, Brakenhoff J, de Groot E, et al. Interleukin 6 is involved in interleukin-1-induced activities. Eur J Immunol 1988; 18: 957–9

    Article  PubMed  CAS  Google Scholar 

  61. Marinkovic S, Jahreis GP, Wong GG, et al. IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol 1989; 142: 808–12

    PubMed  CAS  Google Scholar 

  62. Spangel BL, Judd AM, Isakson PC, et al. Interleukin-6 stimulates anterior pituitary hormone release in vitro. Endocrinology 1989; 125: 575–7

    Article  Google Scholar 

  63. Naitoh Y, Fukata J, Tominaga J, et al. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. Biochem Biophys Res Commun 1988; 155: 1459–63

    Article  PubMed  CAS  Google Scholar 

  64. Salas MA, Evans SW, Levell MJ, et al. Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells. Clin Exp Immunol 1990; 470–3

    Google Scholar 

  65. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990; 145: 3297–303

    PubMed  CAS  Google Scholar 

  66. Barton BE, Mayer R. IL-3 and IL-6 do not induce bone resorption in vitro. Cytokine 1990; 2: 217–20

    Article  PubMed  CAS  Google Scholar 

  67. Campbell IL, Cutri A, Wilson A, et al. Evidence for IL-6 production by and effects on the pancreatic β-cell. J Immunol 1989; 143: 1188–91

    PubMed  CAS  Google Scholar 

  68. Sandler S, Bendtzen K, Eizirik DL, et al. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology 1990; 126: 1288–94

    Article  PubMed  CAS  Google Scholar 

  69. Buschard K, Aaen K, Horn T, et al. Interleukin-6: a functional and structural in vitro modulator of beta cells from islets of Langerhans. Autoimmunity 1990; 5: 185–94

    Article  PubMed  CAS  Google Scholar 

  70. Koike K, Nakahata T, Takagi M, et al. Synergism of BSF-2/interleukin 6 and interleukin 3 on development of multipotential hemopoietic progenitors in serum-free culture. J Exp Med 1988; 168: 879–90

    Article  PubMed  CAS  Google Scholar 

  71. Bot FJ, Van Eijk L, Broeders L, et al. Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells. Blood 1989; 73: 435–7

    PubMed  CAS  Google Scholar 

  72. Castell JV, Geiger T, Gross V, et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988; 177: 357–61

    Article  PubMed  CAS  Google Scholar 

  73. Ikebuchi K, Wong GG, Clark SC, et al. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 1987; 84: 9035–9

    Article  PubMed  CAS  Google Scholar 

  74. Leary AG, Ikebuchi K, Hirai Y, et al. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hemopoietic stem cells: comparison with interleukin-1a. Blood 1988; 71: 1759–63

    PubMed  CAS  Google Scholar 

  75. Suziki C, Okano A, Takatsuki F, et al. Continuous perfusion with interleukin-6 (IL-6) enhances production of hematopoietic stem cells (CFU-S). Biochem Biophys Res Commun 1989; 159: 933–8

    Article  Google Scholar 

  76. Patchen ML, MacVittie TJ, Williams JL, et al. Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood 1991; 77: 472–80

    PubMed  CAS  Google Scholar 

  77. Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989; 74: 1241–4

    PubMed  CAS  Google Scholar 

  78. Burstein SA, Downs T, Friese P, et al. Thrombocytopoiesis in normal and sublethally irradiated dogs: response to human interleukin-6. Blood 1992; 80: 420–8

    PubMed  CAS  Google Scholar 

  79. Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 1989; 86: 7547–51

    Article  PubMed  CAS  Google Scholar 

  80. Geissler K, Valent P, Bettelheim P, et al. In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. Blood 1992; 79: 1155–60

    PubMed  CAS  Google Scholar 

  81. Tanaka R, Koike K, Imai T, et al. Stem cell factor enhances proliferation, but not maturation, of murine megakaryocytic progenitors in serum-free culture. Blood 1992; 80: 1743–9

    PubMed  CAS  Google Scholar 

  82. Finke JH, Rayman P, Edinger M, et al. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1991; 11: 1–11

    Article  Google Scholar 

  83. Alexander JP, Kudoh S, Melsop KA, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin-2 and express interleukin-2 receptors. Cancer Res 1993; 53: 1380–7

    PubMed  CAS  Google Scholar 

  84. Finke JH, Rayman P, Hart L, et al. Characterization of tumor infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-γ secretion, and proliferation. J Immunother 1994; 15: 91–104

    Article  CAS  Google Scholar 

  85. Ceuppens JL, Baroja ML, Loire K, et al. Human T cell activation with phytohemagglutinin: the function of IL-6 as an accessory signal. J Immunol 1988; 141: 3868–74

    PubMed  CAS  Google Scholar 

  86. Houssiau FA, Coulie PG, Van Snick J. District roles of IL-1 and IL-6 in human T cell activation. J Immunol 1989; 143: 2520–4

    PubMed  CAS  Google Scholar 

  87. Mulé JJ, McIntosh JK, Jablons DM, et al. Antitumor activity of recombinant interleukin-6 in mice. J Exp Med 1990; 171: 629–36

    Article  PubMed  Google Scholar 

  88. Mulé JJ, Custer MC, Travis W, et al. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 1992; 148: 2622–9

    PubMed  Google Scholar 

  89. Olencki T, Rayman P, Finke J, et al. Antitumor effects of IL-6 alone and in combination with IL-2 and/or cyclophosphamide in the weakly immunogenic murine RENCA tumor [abstract]. Proc Am Assoc Cancer Res 1994; 35: 525

    Google Scholar 

  90. Mullen GA, Coale MM, Levy AT, et al. Fibrosarcoma cells transduced with IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity and decreased metastatic potential. Cancer Res 1992; 52: 6020–4

    PubMed  CAS  Google Scholar 

  91. Sun WH, Kreisle RA, Phillips AW, et al. In vivo and in vitro characteristics of interleukin-6 transfected B16 melanoma cells. Cancer Res 1992; 52: 5412–5

    PubMed  CAS  Google Scholar 

  92. Porgador A, Tzehoval E, Katz A, et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52: 3679–86

    PubMed  CAS  Google Scholar 

  93. Porgador A, Brenner B, Vadai E, et al. Immunization by gamma-IFN-treated B16-F10.9 melanoma cells protects against metastatic spread of the parental tumor. Int J Cancer Suppl 1991; 6: 54–60

    Article  PubMed  CAS  Google Scholar 

  94. Ohe Y, Podack E, Olsen K, et al. Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumor growth rate but cause weight loss and shorter survival in syngenic mice. Br J Cancer 1993; 67: 939–44

    Article  PubMed  CAS  Google Scholar 

  95. Olencki T, Budd GT, Murthy S, et al. Cytokine gene expression and secretion: effects of rhIL-6 in cancer patients [abstract]. Blood 1993; 82: 519a

    Google Scholar 

  96. Thomassen MJ, Antal JM, Connors MJ, et al. Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes. J Immunother 1993; 14: 43–50

    Article  CAS  Google Scholar 

  97. Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993; 11: 499–506

    PubMed  CAS  Google Scholar 

  98. Demetri GD, Samuels B, Gordon M, et al. Recombinant human interleukin-6 (IL-6) increases circulating platelet counts and C-reactive protein levels in vivo: initial results of a phase I trial in sarcoma patients with normal hemopoiesis [abstract]. Blood 1992; 80: 88a

    Google Scholar 

  99. Demetri GD, Bukowski RM, Samuels B, et al. Stimulation of thrombopoiesis by recombinant human interleukin-6 (IL-6) pre- and post-chemotherapy in previously untreated sarcoma patients with normal hematopoiesis [abstract]. Blood 1993; 82: 367a

    Google Scholar 

  100. Chang A, Boros L, Asbury R, et al. Effects of interleukin-6 (rhIL-6) in cancer patients treated with ifosfamide, carboplatin and etoposide (ICE) [abstract]. Proc Am Soc Clin Oncol 1993; 12: 288

    Google Scholar 

  101. Gameren MM, Vellenga E, Willemse PHB, et al. The effects of recombinant human interleukin-6 (rhIL-6) on in vivo hematopoiesis in cancer patients [abstract]. Blood 1992; 80: 249a

    Google Scholar 

  102. Gordon MS, Nemunaitis J, Hoffman R, et al. Phase I trial of subcutaneous (SC) recombinant human interleukin-6 (IL-6) in patients with myelodysplasia (MDS) and thrombocytopenia (TP) [abstract]. Blood 1992; 80: 249a

    Google Scholar 

  103. Lazarus HM, Winton EF, Williams SF, et al. Phase I study of recombinant human interleukin-6 (rhIL-6, E. coli) after autologous bone marrow transplant (ABMT) in patients with poor prognosis breast cancer [abstract]. Blood 1993; 82: 173a

    Google Scholar 

  104. Ritch PS, Schiller J, Rivkin S, et al. Phase I evaluation of recombinant human interleukin-6 [abstract]. Blood 1993; 82: 367a

    Google Scholar 

  105. Fay JW, Collins R, Pineiro L, et al. Concomitant administration of interleukin-6 (rhIL-6) and leucomax (rhGM-CSF) following autologous bone marrow transplantation — a phase I trial [abstract]. Blood 1993; 82: 431

    Google Scholar 

  106. Colwill R, Crump M, Stewart AK, et al. Phase I trial of interleukin-6 (IL-6) after autologous bone marrow transplantation (ABMT) for patients with poor prognosis hodgkin’s disease [abstract]. Blood 1993; 82: 646a

    Google Scholar 

  107. Aronson FR, Sznol M, Mier JW, et al. Interleukin-6: phase I trials of 1 and 120 hour intravenous infusions [abstract]. Proc Am Soc Clin Oncol 1993; 12: 292

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental Therapeutics Program, Cleveland Clinic Cancer Center, 9500 Euclid Avenue, Cleveland, Ohio, 44195, USA

    Thomas Olencki &  Ronald M. Bukowski

  2. Department of Immunology, Cleveland Clinic Research Institute, Cleveland, Ohio, USA

    James Finke &  Ronald M. Bukowski

Authors
  1. Thomas Olencki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ronald M. Bukowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olencki, T., Finke, J. & Bukowski, R.M. Interleukin-6. Clin. Immunother. 2, 278–294 (1994). https://doi.org/10.1007/BF03258528

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03258528

Keywords

Search

Navigation